Hormonal and Antihormonal Therapy for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Laryngoscope

Volumn 114, Issue 4, 2004, Pages 705-709

  Jameson, John J ^a,b   Cave, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Estrogen; Hereditary hemorrhagic telangiectasia; Hormonal therapy; Tamoxifen

Indexed keywords

ANDROGEN; ANTIESTROGEN; CONJUGATED ESTROGEN; CYCLOSPORIN; DANAZOL; DIENESTROL; DILTIAZEM; ERYTHROMYCIN; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MESTRANOL PLUS NORETYNODREL; NIFEDIPINE; PROGESTERONE; TAMOXIFEN; TESTOSTERONE; WARFARIN;

ADULT; ARGON PLASMA COAGULATION; BLOOD TRANSFUSION; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; BREAST TUMOR; CASE REPORT; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; ENDOMETRIUM CANCER; EPISTAXIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIVER TUMOR; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; METAPLASIA; MONOTHERAPY; MOOD DISORDER; NAUSEA; PERIPHERAL EDEMA; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; REVIEW; SIDE EFFECT; TESTIS ATROPHY; THROMBOEMBOLISM; UTERINE CERVIX DISEASE; UTERINE CERVIX TUMOR; UTERUS TUMOR; VAGINA BLEEDING; VAGINA DISCHARGE; WEIGHT GAIN; DRUG ADMINISTRATION; DRUG COMBINATION; MALE; MIDDLE AGED;

DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EPISTAXIS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGESTERONE; TAMOXIFEN; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 1842505675     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200404000-00021     Document Type: Review

References (33)

1. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
2. Berg J, Porteous M, Reinhardt D, et al. Hereditary hemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet 2003;40:585-590.
3. Assar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991;101:977-980.
4. Menefee MG, Flessa HC, Glueck HI, Hogg SP. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): an electron microscopic study of the vascular lesions before and after therapy with hormones. Arch Otolaryngol 1975; 101:246-251.
5. Pau H, Carney AS, Murty GE. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol 2001;26: 93-98.
6. Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2003;36:149-158.
7. Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope 2002;112:767-773.
8. Reilly PJ, Nostrant TT. Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol 1984;79: 363-367.
9. Shapshay SM, Oliver P. Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope 1984;94:1554-1556.
10. Pohar S, Mazeron JJ, Ghilezan M, Le Bourgeois JP, Pierquin B. Management of epistaxis in Rendu-Osler disease: is brachytherapy effective? Int J Radiat Oncol Biol Phys 1993;27:1073-1077.
11. Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994;330:1789-1790.
12. Klepfish A, Berrebi A, Schattner A, Israel R. Intranasal tranexamic acid treatment for severe epistaxis in hereditary, hemorrhagic telangiectasia. Arch Intern Med 2001;161: 767.
13. Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic telangiectasia. JAMA 1952;149: 1376-1380.
14. Harrison DFN. Familial haemorrhagic telangiectasias: 20 cases treated with systemic oestrogen. Q J Med 1964;33: 25-38.
15. Harrison DFN. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 1982;92:314-320.
16. Blackburn EK. Long-term treatment of epistaxis with oestrogens. BMJ 1963;20:150-160.
17. Flessa HC, Glueck HI. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977;103:148-151.
18. Van Cutsem E, Rutgeerts P, Geboes K, Van Gompel F, Vantrappen G. Estrogen-progesterone treatment of Osler-Weber-Rendu disease. J Clin Gastroenterol 1988;10: 676-679.
19. Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953-955.
20. Richtsmeier W, Weaver G, Streck W, Jacobson H, Dewell R, Olson J. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1984;92:564-570.
21. Tombleson PMJ. Local oestrogen for recurrent epistaxis caused by familial telangiectasia. J Roy Coll Gen Pract 1988;May:227.
22. Sadick H, Riedel F, Oulmi J, Hormann K, Bergler WF. [Argon plasma coagulation and topically applied estriol: long-term results in the treatment of hereditary hemorrhagic telangiectasia of the nasal mucosa.] HNO 2003;51:118-124.
23. Haq AU, Glass J, Netchvolodoff CV, Bowen LM. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med 1988;109:171.
24. Longacre AV, Gross CP, Gallitelli M, Henderson KJ, White RI Jr, Proctor DD. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2003;98:59-65.
25. Zacharski LR, Dunbar SD, Newsom, Jr WA. Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia. Thromb Haemost 2001;85:371-372.
26. Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia: a double-blind controlled clinical trial. Acta Med Scand 1981;209:393-396.
27. Rowley PT, Kurnick J, Cheville R. Hereditary haemorrhagic telangiectasia: aggravation by oral contraceptives? Lancet 1970;1:474-475.
28. McCaffrey TV, Kern EB, Lake CF. Management of epistaxis in hereditary hemorrhagic telangiectasia: review of 80 cases. Arch Otolaryngol 1977;103:627-630.
29. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001;121:1073-1079.
30. Bronner MH, Pate MB, Cunningham JT, Marsh WH. Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. Ann Intern Med 1986;105:371-374.
31. Pau H, Carney AS, Walker R, Murty GE. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia? A biochemical evaluation. Clin Otolaryngol 2000;25:547-550.
32. Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74: 74-77.
33. Wooltorton E. Tamoxifen for breast cancer prevention: safety warning. CMAJ 2002;167:378-379.